SCHEMBL738191

SCHEMBL738191

COC1CCN(C(=O)C(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
DPP4 P27487 1/20 0.44
DPP7 Q9UHL4 1/20 0.44
CHRNB2 P17787 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
CHRNB3 Q05901 1/20 0.41
CHRNA6 Q15825 1/20 0.41
HRH3 Q9Y5N1 3/20 0.40
PDE4B Q07343 1/20 0.40
HPGD P15428 1/20 0.40
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
PDE9A O76083 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NAMPT P43490 2/20 0.38
EPHX2 P34913 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23134526 0.93 DPP4 (0.40) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL739765 0.89 PDE4B (0.44) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL22000200 0.89 PDE4B (0.44) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL27405335 0.89 PDE4B (0.44) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL10328343 0.86 KMT2A (0.43) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL12521996 0.86 KMT2A (0.43) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL27425180 0.86 MEN1 (0.46) KMT2AMEN1ALDH1A1CHRNB2CHRNA3
SCHEMBL12522241 0.85 HPGD (0.44) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL15045201 0.85 DPP4 (0.49) KMT2AMEN1ALDH1A1DPP4DPP7
SCHEMBL17308242 0.82 DPP4 (0.43) KMT2AMEN1ALDH1A1DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3189042-B1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2021-03-17 EP disclosed
WO-2020132582-A1 STING AGONISTS AND USES THEREOF NIMBUS TITAN, INC. (US) 2020-06-25 WO disclosed
US-10647708-B2 Tetrahydroisoquinoline derived PRMT5-inhibitors CTXT PTY. LTD (AU) 2020-05-12 US disclosed
WO-2020072391-A1 SMALL MOLECULE MENIN INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-04-09 WO disclosed
US-10550096-B2 Tetrahydroisoquinolines as PRMT5 inhibitors CTXT PTY LTD (AU) 2020-02-04 US disclosed
US-10428080-B2 TBK/IKK inhibitor compounds and uses thereof MERCK PATENT GMBH (DE) 2019-10-01 US disclosed
US-10421743-B2 Tetrahydroisoquinolines as PRMT5 inhibitors CTXT PTY LTD (AU) 2019-09-24 US disclosed
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
WO-2019047915-A1 IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS BEIGENE, LTD. (KY) 2019-03-14 WO disclosed
US-20190071425-A1 TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS CTXT PTY LTD (AU) 2019-03-07 US disclosed
US-9988391-B2 TBK/IKK inhibitor compounds and uses thereof MERCK PATENT GMBH (DE) 2018-06-05 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170313713-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-11-02 US disclosed
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-19 US disclosed
US-20170283407-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-05 US disclosed
US-20160376283-A1 TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-12-29 US disclosed
US-8138181-B2 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-03-20 US disclosed
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-06-10 US disclosed
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313713-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 KMT2A 55/4885MEN1 586/4885ALDH1A1 2910/4885
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 KMT2A 543/4885MEN1 2334/4885ALDH1A1 717/4885
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 KMT2A 1354/4885MEN1 3157/4885ALDH1A1 405/4885
US-10428080-B2 TBK/IKK inhibitor compounds and uses thereof NFKBIA, TBKBP1, TBK1 KMT2A 2730/4885MEN1 4009/4885ALDH1A1 4646/4885
US-10647708-B2 Tetrahydroisoquinoline derived PRMT5-inhibitors PRMT5, PRMT3, PRMT1 KMT2A 34/4885MEN1 367/4885ALDH1A1 4354/4885
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 KMT2A 38/4885MEN1 324/4885ALDH1A1 4190/4885
US-20190071425-A1 TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KMT2A 46/4885MEN1 162/4885ALDH1A1 4294/4885
US-10421743-B2 Tetrahydroisoquinolines as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 KMT2A 46/4885MEN1 162/4885ALDH1A1 4294/4885
US-10550096-B2 Tetrahydroisoquinolines as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 KMT2A 53/4885MEN1 384/4885ALDH1A1 4296/4885
US-20170283407-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT3, PRMT1 KMT2A 34/4885MEN1 367/4885ALDH1A1 4354/4885
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 KMT2A 165/4885MEN1 1364/4885ALDH1A1 1563/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 KMT2A 165/4885MEN1 1364/4885ALDH1A1 1563/4885
US-20160376283-A1 TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF NFKBIA, TBKBP1, TBK1 KMT2A 2730/4885MEN1 4009/4885ALDH1A1 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.